FDA: CAR T-Cell Therapies May Increase Risk for Rare Secondary Cancers
Twenty-five reports of rare blood cancers in patients who had received CAR T-cell therapy prompted agency's warning
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.